Published in Inflamm Allergy Drug Targets on December 01, 2008
A large-scale, consortium-based genomewide association study of asthma. N Engl J Med (2010) 9.17
Dioxin and immune regulation: emerging role of aryl hydrocarbon receptor in the generation of regulatory T cells. Ann N Y Acad Sci (2010) 1.34
T-cell regulation in lepromatous leprosy. PLoS Negl Trop Dis (2014) 0.91
Expression of IL-7 receptor in human peripheral regulatory T cells. Arch Med Sci (2012) 0.91
IL-4 and TGF-beta 1 counterbalance one another while regulating mast cell homeostasis. J Immunol (2010) 0.90
Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog. Immunology (2010) 0.86
TGF-beta can leave you breathless. Curr Opin Pharmacol (2009) 0.85
Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin-induced asthma model through the induction of regulatory T cells. Immun Inflamm Dis (2015) 0.83
T cell transcriptional factors in allergic rhinitis and its association with clinical features. Asia Pac Allergy (2013) 0.83
Milk: a postnatal imprinting system stabilizing FoxP3 expression and regulatory T cell differentiation. Clin Transl Allergy (2016) 0.78
Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. Hum Vaccin Immunother (2013) 0.78
Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma. Respir Res (2011) 0.77
Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol (2013) 0.77
Induction of eosinophil apoptosis by hydrogen peroxide promotes the resolution of allergic inflammation. Cell Death Dis (2015) 0.76
Herbal Medicine Cordyceps sinensis Improves Health-Related Quality of Life in Moderate-to-Severe Asthma. Evid Based Complement Alternat Med (2016) 0.75
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 4.10
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40
Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet (2005) 2.07
Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol (2003) 2.01
Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.87
Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol (2007) 1.85
Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol (2006) 1.68
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65
Tregs and allergic disease. J Clin Invest (2004) 1.64
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol (2011) 1.62
Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45
Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol (2008) 1.43
Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol (2008) 1.38
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol (2005) 1.30
Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol (2007) 1.28
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol (2010) 1.27
Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol (2004) 1.26
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.26
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol (2007) 1.22
The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol (2003) 1.13
Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol (2007) 1.12
Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol (2005) 1.12
Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc (2004) 1.09
Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol (2012) 1.08
Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol (2012) 1.08
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol (2007) 1.06
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy (2012) 1.04
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol (2011) 1.02
Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol (2003) 1.02
IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol (2005) 1.01
Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00
Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol (2003) 0.99
CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol (2002) 0.99
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol (2004) 0.98
IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am (2006) 0.97
IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 0.96
Germinal-centre reactions in allergic inflammation. Trends Immunol (2006) 0.95
Allergen immunotherapy and tolerance. Allergol Int (2013) 0.92
NHS allergy services in the UK: proposals to improve allergy care. Clin Med (2002) 0.91
One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol (2011) 0.90
Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther (2013) 0.90
Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J Allergy Clin Immunol (2005) 0.89
Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am (2011) 0.88
Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol (2004) 0.87
Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med (2002) 0.86
Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res (2006) 0.85
The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol (2010) 0.84
Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax (2013) 0.83
CXCR1+CD4+ T cells in human allergic disease. J Immunol (2004) 0.83
Postnasal drip and chronic cough: An open interventional study. Respir Med (2009) 0.82
Tobacco industry lobbyists and their health-care clients. Lancet (2013) 0.82
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol (2012) 0.82
Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol (2012) 0.81
Mechanisms of sublingual immunotherapy. Immunol Allergy Clin North Am (2011) 0.81
Immunological responses to allergen immunotherapy. Clin Allergy Immunol (2004) 0.81
Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol (2013) 0.80
Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother (2012) 0.79
Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep (2002) 0.78
Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin Transl Allergy (2013) 0.77
Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE? J Allergy Clin Immunol (2009) 0.77
Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol (2008) 0.76
Immunomodulatory treatment strategies for allergic diseases. Curr Drug Targets Inflamm Allergy (2003) 0.76
Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med (2006) 0.75
Treatment of seasonal allergic rhinitis: desensitisation for hay fever works. BMJ (2003) 0.75
Perennial rhinitis. BMJ (2007) 0.75
Tradition and innovation: finding the right balance. J Allergy Clin Immunol (2007) 0.75
Biomarkers of tolerance in response to allergen immunotherapy. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess (2013) 0.75
Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol (2008) 0.75
Silk contact anaphylaxis. Contact Dermatitis (2014) 0.75
Allergen injection immunotherapy. Clin Allergy Immunol (2002) 0.75